Health
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation te
About this update from Nexalin Technology, Inc.
[{"type":"image","alt":"Nexalin Technology, Inc.","displaySize":"","headline":null,"caption":"Nexalin Technology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kPm7LNc3A4iAJ.KL_fneQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76","width":200,"height":200}},"lazy":false},{"type":"text","content":"Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques","length":180,"tagName":"p"},{"type":"text","content":"HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its “mood-military-memory” clinical business plan with the FDA by publishing and submitting extensive clinical data.","length":534,"tagName":"p"},{"type":"text","content":"Recent peer-reviewed and published data collectively span Insomnia and Depression (mood), traumatic brain injury and PTSD (military), Alzheimer’s disease (memory), and, most recently, attention deficit hyperactivity disorder (ADHD). Together, this body of clinical evidence continues to support Nexalin’s clinical business plan presented in recent pre-submission meetings with the FDA.","length":385,"tagName":"p"},{"type":"text","content":"Nexalin’s growing body of published data consistently demonstrates objective normalization of abnormal brain activity and network function. This normalization of abnormal brain function is validated through traditional patient symptom surveys, advanced neuroimaging, and other bioelectrical biomarkers administered pre- and post-treatment.","length":339,"tagName":"p"},{"type":"text","content":"Unlike inferior proposed neurostimulation devices that rely on minimal localized, surface-level stimulation, Nexalin’s clinical research has consistently incorporated o...